Search results
Results from the Tech24 Deals Content Network
Patient portals are healthcare -related online applications that allow patients to interact and communicate with their healthcare providers, such as physicians and hospitals. Typically, portal services are available on the Internet at all hours of the day and night. Some patient portal applications exist as stand-alone web sites and sell their ...
Patient First is a chain of urgent care centers in the United States. The centers allow patients to walk in and receive diagnosis and treatments for common symptoms and ailments [1] that can receive outpatient care without an appointment. The company, which is based in Glen Allen, Virginia, currently has locations in Maryland, Pennsylvania, New ...
Protected health information ( PHI) under U.S. law is any information about health status, provision of health care, or payment for health care that is created or collected by a Covered Entity (or a Business Associate of a Covered Entity), and can be linked to a specific individual. This is interpreted rather broadly and includes any part of a ...
The whole future of healthcare is going to focus on the ability to securely share data. To empower providers and patients to take control of their healthcare journey, we need to build a system of ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Omron's VitalSight aims to do the same for hypertension, or high blood pressure, which can be a precursor to a stroke or heart attack. The company has a reputation for high quality smart blood ...
The Chesapeake Regional Information System for our Patients (CRISP) is a nonprofit organization created to function as Maryland's state-designated health information exchange (HIE), by the Maryland Health Care Commission. CRISP currently serves as the HIE for Maryland and the District of Columbia. CRISP is advised by a wide range of ...
Patients were randomized to either get one of three doses of pemvidutide or a placebo for 48 weeks. Researchers found that patients who got the highest dose of the drug lost on average 15.6% of ...